Petrus Trust Company LTA Acquires New Holdings in Bruker Corporation $BRKR

Key Points

• Petrus Trust Company LTA acquired a new stake of 22,917 shares in Bruker Corporation worth approximately $957,000 during the first quarter.
• Bruker's recent quarterly earnings report indicated an EPS of $0.32, missing analysts' estimates by 1 cent, along with a revenue of $797.40 million, down 0.4% year-over-year.
• Analysts' target prices for Bruker range between $38.00 and $60.00, with a consensus rating of "Hold" and an average target price of $51.30.

Petrus Trust Company LTA acquired a new stake in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 22,917 shares of the medical research company's stock, valued at approximately $957,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pinnacle Bancorp Inc. bought a new stake in Bruker during the first quarter valued at approximately $29,000. Allworth Financial LP grew its position in shares of Bruker by 92.4% during the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock valued at $30,000 after acquiring an additional 364 shares during the period. Caitong International Asset Management Co. Ltd grew its position in shares of Bruker by 1,354.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company's stock valued at $33,000 after acquiring an additional 745 shares during the period. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in shares of Bruker in the 1st quarter worth $42,000. Finally, MassMutual Private Wealth & Trust FSB raised its holdings in Bruker by 274.9% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock worth $46,000 after purchasing an additional 800 shares during the period. Hedge funds and other institutional investors own 79.52% of the company's stock.

Bruker Price Performance

Shares of BRKR traded up $1.58 during mid-day trading on Thursday, hitting $32.07. 3,664,017 shares of the stock were exchanged, compared to its average volume of 2,674,129. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61. The company has a market cap of $4.87 billion, a PE ratio of 61.67, a price-to-earnings-growth ratio of 4.33 and a beta of 1.21. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $72.94. The firm has a 50-day moving average of $36.46 and a two-hundred day moving average of $39.25.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The firm had revenue of $797.40 million during the quarter, compared to analysts' expectations of $811.17 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%.The business's revenue for the quarter was down .4% compared to the same quarter last year. During the same period last year, the company earned $0.52 earnings per share. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, equities analysts predict that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd will be paid a dividend of $0.05 per share. The ex-dividend date is Tuesday, September 23rd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. Bruker's dividend payout ratio (DPR) is currently 38.46%.

Analyst Upgrades and Downgrades

BRKR has been the subject of a number of analyst reports. Barclays reduced their price target on Bruker from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Monday, August 4th. Jefferies Financial Group set a $60.00 price target on shares of Bruker and gave the company a "buy" rating in a report on Monday, August 4th. Wells Fargo & Company dropped their price target on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating for the company in a research report on Tuesday, August 5th. Citigroup decreased their price objective on shares of Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a research report on Monday, August 4th. Finally, Bank of America dropped their target price on shares of Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Five investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $51.30.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.